Neprilysin
Neprilysin Molecule Information
Name:Neprilysin
Target Synonym:EC:3.4.24.11,MME,Enkephalinase,CALLA,Neutral endopeptidase,Common acute lymphocytic leukemia antigen,Neprilysin,CD10,Membrane Metalloendopeptidase,Neutral Endopeptidase 24.11,Atriopeptidase,NEP,SFE,Membrane Metallo-Endopeptidase (Neutral Endopeptidase, En
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved
Neprilysin Protein Product ListCompare or Buy
Neprilysin Molecule Synonym Name
MME,CALLA,CD10,DKFZp686O16152,MGC126681,MGC126707,NEP,SFE,Neprilysin
Neprilysin Molecule Background
Cluster of differentiation 10 (CD10) is also known as membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, and common acute lymphoblastic leukemia antigen (CALLA), is a 90-110-kDa type II transmembrane glycoprotein normally expressed by a variety of tissues, including epithelial cells of the prostate, kidney, intestine, endometrium, adrenal glands, and lung. This zinc-dependent metalloprotease enzyme cleaves peptide bonds on the amino side of hydrophobic residues and inactivates a variety of physiologically active secreted peptides. CD20 is thought to be the rate-limiting degrading enzyme of amyloid ¦Â peptide (A¦Â) whose abnormal misfolding and aggregation in neural tissue has been implicated in the development of Alzheimer's disease (AD). CD10 is also identified as the common acute lymphoblastic leukemia antigen (CALLA) present on leukemic cells of pre-B phenotype, and thus serves as the most important biomarker in the diagnosis of human acute lymphocytic leukemia (ALL).
Neprilysin References
- Pardossi-Piquard, et al. 2006, Journal of Neurochemistry 97 (4): 1052¨C6.
- Goodman, O.B. et al., 2006, J. Biol. Chem. 281: 33597-33605.
- Cohen, A.J. 1996, Cancer. Res. 56: 831-839.
- Shipp M A,. et al., Proc Natl Acad Sci U S A., 86(1): 297-301.
Neprilysin Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Racecadotril |
Tiorfan; Hidrasec |
Approved |
Bioprojet Pharma |
|
Mainland China |
Diarrhea |
s:16:"Bioprojet Pharma"; |
1993-03-23 |
Diarrhea, Infantile; Diarrhea |
Details
|
| Sacubitril/Valsartan Sodium Hydrate |
LCZ-696 |
Approved |
Novartis Pharma Ag |
诺欣妥, Entresto |
Japan |
Heart Failure |
s:18:"Novartis Pharma Ag"; |
2015-07-07 |
Erectile Dysfunction; Heart Failure; Renal Insufficiency; Myocardial Infarction; Cardiomyopathy, Hypertrophic; Postmyocardial Infarction Syndrome; Hypertension; Essential Hypertension; Hepatic Insufficiency; Lymphoma; Ventricular Dysfunction, Left; Heart Failure, Systolic |
Details
|
Neprilysin Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| Dexecadotril |
|
Phase 3 Clinical |
Bioprojet Pharma |
Gastrointestinal Diseases |
Details
|
| Sacubitril |
AHU-377 |
Phase 2 Clinical |
Novartis Pharma Ag |
Heart Failure; Cardiomyopathy, Hypertrophic; Hypertension; Essential Hypertension |
Details
|
| Debio-0827 |
PL-37; Debio-0827 |
Phase 2 Clinical |
Pharmaleads |
Pain |
Details
|
| LHW-090 |
LHV-527; LHW-090 |
Phase 2 Clinical |
Novartis Pharma Ag |
Hypertension; Renal Insufficiency, Chronic |
Details
|
| Sacubitril/Allisartan Isoproxil |
S-086; AHU-377/EXP3174 |
Phase 2 Clinical |
Shenzhen Salubris Pharmaceuticals Co Ltd |
Heart Failure; Hypertension; Essential Hypertension |
Details
|
| STR-324 |
STR-324 |
Phase 2 Clinical |
Shanghai Pasteur Institute Of Chinese Academy Of Sciences |
Pain; Acute Pain |
Details
|
A-Z